Biomarker profiles of acute rejection in liver transplant recipients could enhance the diagnosis and management of recipients. Our aim was to identify diagnostic proteoform signatures of acute rejection in circulating immune cells, using an emergent "topdown" proteomics methodology. We prepared differentially processed and cryopreserved cell lysates from 26 nonviral liver transplant recipients by molecular weight-based fractionation and analyzed them by mass spectrometry of whole proteins in three steps: (i) Nanocapillary liquid chromatography coupled with high-resolution tandem mass spectrometry; (ii) database searching to identify and characterize intact proteoforms; (iii) data processing through a hierarchical linear model matching the study design to quantify proteoform fold changes in patients with rejection versus normal liver function versus acute dysfunction without rejection. Differentially expressed proteoforms were seen in patients with rejection versus normal and nonspecific controls, most evidently in the cell preparations stored in traditional serum-rich media. Mapping analysis of these proteins back to genes through gene ontology and pathway analysis tools revealed multiple signaling pathways, including inflammation mediated by cytokines and chemokines. Larger studies are needed to validate these novel rejection signatures and test their predictive value for use in clinical management.
Biomarker profiles of acute rejection in liver transplant recipients could enhance the diagnosis and management of recipients. Our aim was to identify diagnostic proteoform signatures of acute rejection in circulating immune cells, using an emergent "topdown" proteomics methodology. We prepared differentially processed and cryopreserved cell lysates from 26 nonviral liver transplant recipients by molecular weight-based fractionation and analyzed them by mass spectrometry of whole proteins in three steps: (i) Nanocapillary liquid chromatography coupled with high-resolution tandem mass spectrometry; (ii) database searching to identify and characterize intact proteoforms; (iii) data processing through a hierarchical linear model matching the study design to quantify proteoform fold changes in patients with rejection versus normal liver function versus acute dysfunction without rejection. Differentially expressed proteoforms were seen in patients with rejection versus normal and nonspecific controls, most evidently in the cell preparations stored in traditional serum-rich media. Mapping analysis of these proteins back to genes through gene ontology and pathway analysis tools revealed multiple signaling pathways, including inflammation mediated by cytokines and chemokines. Larger studies are needed to validate these novel rejection signatures and test their predictive value for use in clinical management.
Introduction
Acute rejection (AR) has historically been a major contributor to liver transplant (LT) morbidity and mortality. Although data from the 1990s showed that AR did not significantly affect outcomes, more recent patient cohort data indicate that AR is associated with a nearly twofold risk of death and graft failure (1, 2) . Given the importance of AR, the availability of clinically serviceable biomarkers of immune activation could allow patient management to be individualized to avoid AR events during immunosuppression modifications. Prior studies have focused on recipient DNA polymorphisms, biopsy RNA expression, and serum microRNA for AR prediction and diagnosis (3) (4) (5) (6) . Few studies have analyzed protein expression in the peripheral blood, which represents viable cellular function and metabolically active byproducts of immune activation in a minimally invasive test.
The large-scale study of the proteome, or proteomics, has become increasingly prevalent in translational research. Most mass spectrometry (MS)-based proteomics is dependent on preanalytical digestion of proteomes, which yields proteome coverage that lacks specificity due to an inference step that predicts protein species from experimentally observed peptides (7) . These "bottom-up" methodologies often cannot inform researchers about the posttranslational modifications (PTMs) and sequence variants that are operative in complex phenotypes. In contrast, top-down proteomics (TDP) is an emergent technology in translational research that negates the need for digestion through sample processing, MS instrumentation, and informatics designed for direct analysis of whole proteins (8) . By forgoing digestion, TDP directly measures intact proteins including all of their chemical and genetic complexity, referred to as proteoforms (9) . Proteoforms are more closely connected to resultant phenotypes than peptides and may serve as higher quality, specific biomarkers while providing complementary insights into disease mechanisms (10) . Although not widespread, TDP has recently been applied to the proteomic profiling of AR in peripheral blood mononuclear cells (PBMCs) of kidney transplant patients, identifying candidate molecules of immunemediated allograft damage (11).
In the genomics age, cells were banked in biorepositories for transcriptomic studies that necessitated their storage in RNA-stabilizing media (e.g. RNAlater [Qiagen Inc., Germantown, MD]) (12) . Due to the cell-lytic effect of RNAlater, we refer to RNAlater-stored cells as "nonviable" and cells stored in traditional media as "viable." Because of the importance of preanalytical sample preparation in protein recovery and solubility for the analysis of whole proteoforms, it is critical to determine which preparation (viable or nonviable) would be most applicable to future TDP studies. Our goal in this study was twofold: (i) to test the hypothesis that there is a distinct PBMC proteoform signature of AR in LT recipients and (ii) to test the assertion that using viable cells is ideal for TDP studies by reducing preanalytical variation. These data will help guide future studies of proteoform biomarkers as serial measures for predicting and diagnosing AR.
Methods

Patient enrollment and biopsy analysis
Starting in 2010, consecutive LT recipients at Northwestern consented to have blood samples collected at the time of an indication ("for cause") liver biopsy. Informed consent was obtained from each participant, and the corresponding institutional ethics committees approved the study protocol. For this study, only patients negative for hepatitis B and hepatitis C virus (HCV) were included to avoid the confounding effect of viral disease on protein expression in AR. Peripheral blood was collected in cell preparation tubes (catalog no. 362761; BD Biosciences, San Jose, CA) on the same day and immediately prior to the biopsy procedure (only one biopsy per patient), and PBMCs were isolated according to the manufacturer's instructions. The blood collection was divided into viable and nonviable cell samples. Viable cells were preserved in serum-rich freeze media, whereas nonviable cell samples were emulsified in RNAlater (catalog no. 76106; Qiagen, Hilden, Germany) and frozen. Demographic, laboratory, and clinical course data were collected from the Northwestern Medicine Enterprise Data Warehouse, a comprehensive, integrated clinical repository of multiple data sources at Northwestern Memorial Hospital. Our posttransplant immunosuppression protocol does not include induction therapy and generally consists of tacrolimus (trough levels month 0-1, 1-6, >6: 10-12, 8-10, 3-8 lg/L, respectively), corticosteroids (weaned off by 3-6 mo), and mycophenolate mofetil in approximately 50% of recipients.
The biopsies were reviewed locally for clinical care and then sent to the University of Pittsburgh Medical Center (A.J.D.) for a separate, blinded central review. Rejection was scored using the Banff rejection activity index (RAI) (13) . Clinical data were recorded by a transplant hepatologist (J.L), and a final phenotypic category was selected based on the biopsy and clinical course: (i) AR: RAI score ≥3 in non-HCV patients; (ii) acute dysfunction, no rejection (ADNR): other histology not representing AR; (iii) transplant excellent (TX): LT recipients with normal liver function tests (≤ times upper limit of normal at the time of and 3 mo before or after collection). Because programs do not generally perform protocol liver biopsies in recipients with normal liver tests, we included such TX patients as clinically and biochemically "normal."
Sample preparation of viable and nonviable PBMCs
Viable and nonviable PBMCs from the same cohort of non-HCV plus LT recipients undergoing liver biopsy were quickly thawed, lysed, and quantified for protein content by bicinchoninic acid (BCA) assay. For each patient, 100 lg of protein was processed by gel-eluted liquid fraction entrapment electrophoresis (GELFrEE) using an 8% cartridge (catalog no. 42103; Expedeon, San Diego, CA) to create a single fraction containing all proteins from 0-30 kDa. An extra treatment of high-speed centrifugation prior to BCA quantitation removed RNAlater in nonviable lysates. GELFrEE fractions for downstream mass analysis were desalted by methanol/chloroform/water precipitation (14) , and proteins were resuspended in buffer A (95% H 2 O, 5% acetonitrile, 0.2% formic acid) for liquid chromatography (LC) and MS.
LC-MS/MS and data processing
Protein fractions were analyzed in technical quadruplicate by several steps (Figure 1 ), as described previously (11) . First, proteoforms were separated by nanocapillary LC using a PepSwift monolithic trap column (5 mm 9 200 lm; catalog no. 164558; Thermo Fisher Scientific, Waltham, MA) and ProSwift RP4H analytical column (50 cm 9 100 lm; catalog no. 164921; Thermo Fisher Scientific) coupled with a custom electrospray ionization (ESI) source equipped with a PicoTip spray emitter (catalog no. FS360-50-15-N-20-C12; New Objective, Woburn, MA). Proteoforms were analyzed online after nano-ESI on an LTQ Velos Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) operated in data-dependent mode using established instrument methods (15) . Resultant data files were processed through TDPortal, a new search environment on the Quest high-performance computing cluster at Northwestern University, to identify intact proteins and to characterize proteoforms by database searching and scoring. Briefly, TDPortal generated linked sets of precursor and fragmentation data from .raw files, which were searched against a highly annotated version of the Human UniProt Knowledge Base using a three-tiered search tree (files accessible at http://www.topdownproteomics.org/data) (11) .
Statistical analysis and proteoform quantitation
Baseline demographics and clinical characteristics were reported for the three groups and compared. Probability scores and proteoform characterization scores were generated according to established methods to measure the confidence of proteoform identification and characterization (16) . For the high-throughput proteoform identification, statistical methods were adopted to control for multiple testing and to calculate a global false discovery rate (FDR) for the study (17) . For quantitation, least squares means estimates from a hierarchical linear model of ion intensity associated with proteoform signals across data files were used to estimate fold changes in TX, AR, and ADNR patients, using SAS software (SAS Institute, Cary, NC). An additional ANOVA analysis of standardized proteoform intensities across treatments allowed determination of differentially expressed proteoforms (DEPs). All p-values were corrected for multiple testing (18) . Standardized expression levels were used to avoid the upward bias associated with the multiplicative nature of measurement errors in Fourier transform MS. Detailed information on the statistical procedures used for these data is provided in the Supplementary Methods.
Results
Recipient characteristics
In total, 26 LT recipients were enrolled and had samples collected. Table 1 displays the baseline characteristics of the cohort. Notably, the recipients with AR were younger, were less often white, were closer to the time of LT, and had the most significant liver test abnormalities.
TDP of viable versus nonviable PBMCs
Across the viable cell study, 1099 proteoforms corresponding to 217 UniProt Knowledgebase protein accession numbers were identified at <5% global FDR threshold (full report in Data S1). All confidently characterized proteoforms (characterization score >40) from this study are publicly accessible in the Proteoform Repository (http://repository.topdownproteomics.org/). In total, 135 ) from blood collection to informatics analysis. Label-free top-down quantitation in translational research is a complex methodology with many aspects. First, patients were stratified into three groups by independent pathologist review to confirm phenotypic assignments. TX patients showed no signs of allograft dysfunction, AR patients demonstrated rejection activity index scores ≥3, and ADNR patients were included as a nonspecific liver dysfunction control. In all three phenotypes, PBMCs were collected from eight to 10 patients per state. Proteins were resolved by size using gel-eluted liquid fraction entrapment electrophoresis, and the resulting fractions were analyzed by LC-MS in technical quadruplicate and forwarded for ANOVA analysis. LC, liquid chromatography; MS, mass spectrometry; PBMC, peripheral blood mononuclear cell. [Color figure can be viewed at wileyonlinelibrary.com] Label-free, top-down, quantitative analysis describing differentially expressed proteoforms for all three comparisons of the liver transplantation patient groups in this study (AR, TX, and ADNR). For all proteoforms detected in the majority of data files across the data set (open circles), ANOVA was used to assign variation in signal intensity to phenotype-specific effects after accounting for patient-to-patient and technical variation. The x-axis represents the effect size as measured by fold-change (log 2 transformed) between patient groups. The y-axis (FDR-corrected p-value) is a measure of the statistical confidence that signal variation is associated with phenotype. The dashed lines represent our arbitrary thresholds for delineating significant hits: The horizontal dashed line corresponds to a 5% FDR, and vertical dashed lines represent effect sizes 1.4-fold above and below no change. Arrowheads denote certain proteoforms of interest that are discussed in the text. ADNR, acute dysfunction, no rejection; AR, acute rejection; FDR, false discovery rate; PFR, proteoform record number; TX, transplant excellent; CCL, C-C motif chemokine ligand; TYB, thymosin b. [Color figure can be viewed at wileyonlinelibrary.com] proteoforms passed our criteria for quantitation in that they were confidently identified and commonly detected across >50% of the data files. Figure 2 depicts the three patient group comparisons (AR vs. TX, AR vs. ADNR, ADNR vs.
TX) tested by our ANOVA analyses in the form of volcano plots in which the size of the effect is plotted against its significance. Overall, 82 of these proteoforms were quantified at <5% FDR (instantaneous q value generated by ANOVA), which served as an arbitrary confidence threshold in this study. These significant proteoforms were further filtered by a threshold of AE1.4-fold change for DEPs per comparison. Finally, proteoforms that passed effect size and significance thresholds were filtered based on their uniqueness to phenotypes of interest: DEPs up in AR over both TX and ADNR and DEPs up in both TX and ADNR over AR were passed on for deeper analysis (full quantitative output included in Data S2). Table 2 depicts a list of the top 30 DEPs in the comparison of AR and TX.
In the nonviable cell study, only 56 proteoforms were found to be significant, and the majority of these confidently quantified targets demonstrated nondifferential fold-change values. The percentage of signal variation attributable to each level of the study design for every quantified proteoform assigned by the model is displayed in Figure S1 . This analysis suggests that the decrease in quantity of significant hits coming from the nonviable lysate study can be attributed to an increase in variance due to preanalytical variables such as sample treatment, which suppressed detection of biologically significant signals. 
Specific proteoform candidates
The UniProt accession numbers assigned to 57 significant DEPs were parsed by the PANTHER (Protein Analysis Through Evolutionary Relationships) classification tool (19) to identify relevant pathways in immune-mediated rejection ( Figure S2 ). Such pathways associated with the genes that map to the resultant list of significant proteoforms included inflammation mediated by chemokine and cytokine signaling (P00031), TGF-b signaling (P00052), and cadherin-and integrin-mediated signaling (P00012, P00034). In addition, hits were annotated in PANTHER by Gene Ontology (GO) biological processes, further directing filtering of targets by immune system processes (GO:0002376), localization (GO:0051179), locomotion (GO:0040011), and response to stimulus (GO:0050896). Notably, C-C motif chemokine ligand (CCL) 17, CCL5, pro-platelet basic protein (PPBP/CXCL7), and platelet factor 4 (PF4/CXCL4) routinely were identified in our data set of DEPs for immune-related biological processes.
Discussion
Biomarkers of immune activation could significantly improve the management of organ transplant recipients by more specifically guiding immunosuppressive therapy modifications. We have preliminarily identified specific proteoforms in PBMCs of LT recipients that are highly abundant at the time of AR and not during other causes of dysfunction or quiescence. Likewise, the proteoforms associated with TX could be mechanistically important in the control of rejection or may reflect an immune-tolerant state. In addition, we have confirmed that viable cell assays are most ideal for TDP studies in terms of sample quality and protein yield. It can also be argued that the relative lack of treatments performed on viable cells renders them better representations of in vivo immune status. Our proteoform data need validation not only as a diagnostic tool but also during serial modifications of immunosuppression after transplant, with the goal of predicting AR.
Several groups have analyzed blood and tissue samples for biomarkers of rejection in LT and other organ transplant recipients, with mixed results. Efforts at diagnosing rejection with protein-based or genetic biomarkers might have the advantage of avoiding invasive biopsies (20) or improving biopsy accuracy (21, 22) . Donor and recipient polymorphisms have been shown to correlate with the risk of AR but are limited by the lack of serial prediction assessments over time (6) . More appropriate for serial monitoring are circulating microRNA, peripheral blood lymphocyte immunophenotyping, and complement proteins (3, 4) . Predicting rejection or tolerance would allow more specific, real-time optimization of immunosuppression (23) . At this point, there are still no definitive, specific biomarkers available for the prospective monitoring of organ recipients.
Immunological proteoforms may offer more diagnostic utility, mechanistic significance, and identification of therapeutic targets than peptides or epitopes. In addition, analysis of proteoforms may prove more useful in serial assessments by measuring PTMs that are relevant to signaling cascades, histone modifications that direct transcription, and proteolytic processing events that dictate turnover in dynamic proteomes. When combined with other "-omics" approaches, such as global gene expression (21) , TDP can contribute to a systems approach and paint a more complete biological picture of phenotype than these strategies alone. Importantly, an analysis of DEPs in the TX versus AR comparison demonstrates that 47 of 48 proteoforms contain PTMs or variant sequence information that diverge from their canonical sequences. This diversity of posttranslational processing is depicted in Figure 3 (complete list in This preliminary TDP analysis of proteoform signatures in LT PBMCs yields promising targets for future investigation. The most significant DEPs appear to be associated with chemokine/cytokine signaling and cytoskeletal regulation. Proteoforms of CXCL4, for example, were more abundant in TX than AR, and this protein was previously implicated as protective in other transplantation models (24, 25) because of its possible role in blocking Th17 differentiation (26) . Proteoforms of CXCL7 were also more abundant in TX samples, underscoring a putative alloprotective role for associated signaling networks. TDP also characterized a proteoform of CCL5 similar to RANTES (PFR18966), a variant associated with enhanced liver function, that was decreased in AR samples (27) .
Although possible roles for platelet-derived chemokines in rejection are described in the literature, no study has measured specific proteoforms that compose these signals. We identified, for example, 15 proteoforms of CXCL4 and seven proteoforms of CXCL7 resulting primarily from differential N-terminal proteolytic processing, yet only three proteoforms of each were DEPs. This suggests that the molecular specificity introduced by TDP cuts through the biological "noise" introduced by the sequence variants in a particular protein family that do not associate with phenotype. Sequence analysis of CXCL4 DEPs demonstrated the prevalence of three proteoforms in TX patients: the proform (PFR18635), a signal peptide cleavage form (PFR18628), and a previously unknown proteoform (PFR18631). As captured in the in silico digestion experiment depicted in Figure 4 , these proteoforms would not be differentiated by tryptic peptides using classic bottom-up proteomics methodology.
The actin-sequestering proteins thymosin-b4 (TYB4, PFR15875) and thymosin-b10 (TYB10, PFR15911), abundant in AR in our study, may attenuate platelet function (28) and activate hepatic stellate cells responsible for liver fibrosis (29, 30) . In addition, proteoforms of actin-binding proteins, profilin 1 (PFR60623), cofilin 1 (PFR69038, PFR69036), and filamin A (PFR69096, PFR69098), as well as cytoplasmic actin 1 (PFR69028), were highly abundant in the TX group. These preliminary results suggest that a network of actin-binding proteoforms involved in cytoskeletal regulation and resultant morphology perturbations may play a role in AR, as actin cytoskeleton regulation is critical in other immune pathologies (31) .
Although our data are novel in terms of the technology and approach used in this population and the identification of the importance of using viable cells, they still are preliminary and require subsequent high-level scrutiny and verification. Our work is limited by being from a single center without an external validation cohort. We also do not know if these proteoforms are present prior to and thus predictive of AR, as reported with other organ transplant biomarkers (23) . To address these limitations, we plan to test the predictive and diagnostic capability of these proteoforms in further samples from our institution as well as in external serial validation cohorts. It is key to note that specific proteoforms do not necessarily require TDP instrumentation and expertise for measurement but could guide alternative clinically serviceable formats using multiple ELISA or targeted MS-based assays. Direct or indirect measurement of proteoforms could lead to interventional studies in which reducing or augmenting immunosuppression therapy can be guided more optimally by biomarkers signaling immune quiescence or activation, respectively. proteoform intensities across all patients and injections, which were found to be significantly decreased in AR patients. (C) Box-and-whisker plots made from aggregating all PF4/CXCL4 proteoform intensities per patient group to emulate a quantitative comparison using intensities of tryptic peptides, which cannot distinguish the proteoforms. Notably, the effect size is lost to noise in this in silico experiment, and the analysis would return a false negative by bottom-up proteomics. For the box-and-whisker plots, data points represent the normalized intensities of the proteoform of interest yielded from every technical replicate (data file) per patient in which the proteoform was detected (TX: n = 8 patients, 31 data files; ADNR n = 9 patients, 31 data files; AR: n = 9 patients, 33 data files). ADNR, acute dysfunction, no rejection; AR, acute rejection; PF4, platelet factor 4; PFR, proteoform record number; TX, transplant excellent. [Color figure can be viewed at wileyonlinelibrary.com]
Supporting Information
Additional Supporting Information may be found in the online version of this article. Figure S1 : Modeling the components of variation per proteoform by study design hierarchy in viable and nonviable cell treatment workflows. For every proteoform quantified across the nonviable (A) and viable (B) cell studies, variation in signal intensity as a percentage of the total detected for that proteoform was assigned to patient group (TX, AR, or ADNR), biological variation (patient-to-patient variability pooled with experimental variation at the bench), technical variation (replicate LC-MS injections), or residual (unexplained "noise"). Furthermore, an additional level of blocking variation was included for the viable cell study, in which samples were blocked by injection order (this was done to reduce sample degradation over time in the autosampler). The data are depicted as box-and-whisker plots, and every proteoform has a corresponding point in each category of variation so that the final variation calculated per proteoform would sum to 100%. ADNR, acute dysfunction, no rejection; AR, acute rejection; LC, liquid chromatography; MS, mass spectrometry; TX, transplant excellent. Figure S2 : PANTHER pathway and GO biological processes associations for differentially expressed proteoforms representing a putative molecular signature of immune homeostasis in liver transplant patients.
Lists of significant differentially expressed proteoforms across comparisons were parsed for associations with signaling pathways using PANTHER (A). Putative pathways relevant to immune activation are highlighted in red, and accession numbers comprising these associations were extracted for proteoform-resolved analysis and incorporation to a future validation panel. The same protocol was adopted for biological processes by GO analysis (B). GO, Gene Ontology; PANTHER, Protein Analysis Through Evolutionary Relationships. Table S1 : Manually annotated list of posttranslational processing events detected in transplant excellent versus acute rejection patient group comparison, using sequence-variant annotations in the UniProt Knowledgebase for source information.
Data S1: List of identified/characterized proteoforms from high-throughput search.
Data S2: Complete data set from mixed linear model describing quantified proteoform effect sizes and significance for all comparisons.
